CLAIMS

1. Use of allopregnanolone in the manufacture of a medicament for treating post-partum depression in a human subject in need thereof, wherein allopregnanolone is in a sterile aqueous solution comprising 5 mg/mL allopregnanolone in 250 mg/mL sulfobutylether-β-cyclodextrin, the sterile aqueous solution buffered with citrate, wherein the sterile aqueous solution is diluted with sterile water for injection, wherein the diluted solution is to be administered at a dosing regimen over a time period of about 60 hours, wherein the dosing regimen comprises a continuous infusion of:

30 µg/kg/hour from hour 0 to hour 4;

60 µg/kg/hour from hour 4 to hour 24;

90 µg/kg/hour from hour 24 to hour 52;

60 µg/kg/hour from hour 52 to hour 56; and

30 µg/kg/hour from hour 56 to hour 60.

2. The use of claim 1, wherein sulfobutylether-β-cyclodextrin includes a polyanionic beta-cyclodextrin derivative with a sodium sulfonate salt separated by a butyl ether spacer group.